Although various targeted therapies have been developed and applied in lung cancers, a detailed diagnosis of tumor type is important to identify precise treatment \[[@b1-jptm-2020-06-08]\]. Primary lung tumors includes small and non-small cell lung cancers (20% and 80%, respectively) \[[@b2-jptm-2020-06-08]\]. However, the lung is a common metastatic site for metastatic extrapulmonary carcinomas \[[@b3-jptm-2020-06-08]\]. Differential diagnosis between primary lung cancers and metastatic carcinomas to the lung is challenging in some cases due to similar histologic findings or poorly differentiated tumors \[[@b4-jptm-2020-06-08]\]. Although thyroid transcription factor 1 (TTF-1) and Napsin A are useful markers for primary lung adenocarcinoma \[[@b4-jptm-2020-06-08]-[@b7-jptm-2020-06-08]\], complete differentiation between primary lung cancers and metastatic carcinomas to the lung may be limited. Additional precise markers are needed in daily practice.

The paired box transcription factor PAX8 has long been studied in malignant tumors of the lung \[[@b4-jptm-2020-06-08],[@b7-jptm-2020-06-08]-[@b24-jptm-2020-06-08]\]. PAX8, which includes a family of cell-lineage transcription factors, is involved in the organogenesis of the thyroid gland and kidney as well as the Müllerian system. PAX8 can be expressed in the neoplastic cells of associated organs and is expressed both in the normal tissues and tumors from these organs \[[@b25-jptm-2020-06-08]-[@b29-jptm-2020-06-08]\]. In previous studies, high PAX8 expression levels have been shown in kidney, thyroid, ovarian, endometrial, and endocervical carcinomas \[[@b25-jptm-2020-06-08]-[@b32-jptm-2020-06-08]\]. Although PAX8 expression of primary lung cancers was absent in some reports, variable PAX8 expression rates in primary lung cancers has been reported \[[@b4-jptm-2020-06-08],[@b7-jptm-2020-06-08]-[@b24-jptm-2020-06-08]\]. PAX8 expression in normal lung tissue is unclear. In normal lung tissue, various cell types are present, including bronchial epithelium, pneumocytes, submucosal glands, neuroendocrine cells, and lymphocytes, and each has a different PAX8 expression pattern. Moreover, studies have reported PAX8 expression in normal B lymphocytes \[[@b14-jptm-2020-06-08],[@b18-jptm-2020-06-08]\]. These results make interpretation of PAX8 expression in the lung difficult, necessitating a meta-analysis to obtain conclusive information.

Because various malignant tumors including metastatic tumors can occur in the lung, a comparison of PAX8 expression between primary lung cancers and metastatic carcinomas to the lung is needed. In addition, detailed information based on tumor subtypes is not available. In this meta-analysis, we investigated PAX8 immunohistochemical expression rates in primary lung cancers and metastatic carcinomas to the lung as well as in various tumor subtypes of primary lung cancers. Subgroup analysis for PAX8 expression based on the origin of the metastatic carcinomas was also performed.

MATERIALS AND METHODS
=====================

Database search and selection criteria Relevant articles were extracted from the PubMed database through January 31, 2020 using the following keywords: "PAX8," "immunohistochemistry or immunohistochemical," and "cancer or carcinoma." The titles and abstracts of all searched articles were screened. The included articles had information for PAX8 immunohistochemistry of primary lung cancers and metastatic cancers to the lung and metastatic carcinomas from the lung. Additionally, studies on metastatic lung cancers in other organs were included. However, case reports, non-original articles, or articles written in non-English were excluded. We followed PRISMA guidelines.

Data extraction
---------------

Data on the PAX8 immunohistochemical expressions of primary lung cancers and metastatic cancers to the lung and metastatic carcinomas from the lung were extracted from each eligible study \[[@b4-jptm-2020-06-08],[@b8-jptm-2020-06-08]-[@b24-jptm-2020-06-08]\]. All data were extracted by two independent authors. The extracted data included the authors' information, study location, number of patients analyzed, antibody information (manufacturer and clonality), tumor subtypes and PAX8 expression rates.

Statistical analyses
--------------------

The meta-analysis was performed using the Comprehensive Meta-Analysis software package (Biostat, Englewood, NJ, USA). The PAX8 expression rates of various primary lung cancers and metastatic cancers to the lung and the metastatic carcinomas from the lung were investigated. In addition, subgroup analysis was performed based on tumor subtypes of the primary lung cancers and the metastatic carcinoma from the lung. Heterogeneity between studies was checked using Q and I^2^ statistics and is expressed as p-values. Additionally, sensitivity analysis was conducted to assess the heterogeneity of eligible studies and the impact of each study on the combined effects. In the meta-analysis, because the eligible studies used various evaluation criteria and PAX8 antibodies, a random-effect model was more suitable than a fixed-effect model. To assess publication bias, Begg's funnel plot and Egger's test were used. If significant publication bias was found, the fail-safe N and trim-fill tests were additionally used to confirm the degree of publication bias. The results were considered statistically significant at p\<.05.

RESULTS
=======

Selection and characteristics of the studies
--------------------------------------------

In this study, 457 relevant articles were extracted from the PubMed database and reviewed for meta-analysis. Of these, 265 articles with no or insufficient information for a meta-analysis and 122 non-original articles were excluded. Furthermore, 52 articles were excluded for the following reasons: in a language other than English (n=24), on other diseases (n=19), and involving non-human subjects (n=9) ([Fig. 1](#f1-jptm-2020-06-08){ref-type="fig"}). Finally, 18 eligible articles were selected and included in this meta-analysis. These studies included 3,238 patients with primary and metastatic lung cancers ([Table 1](#t1-jptm-2020-06-08){ref-type="table"}).

PAX8 expression in primary lung cancers and metastatic cancers to the lung
--------------------------------------------------------------------------

PAX8 expression rates were estimated in primary lung cancers, including small cell and non-small cell carcinomas. The PAX8 expression rate of overall primary lung cancers was 0.042 (95% confidence interval \[CI\], 0.025 to 0.071). The PAX8 expression rates were 0.129 (95% CI, 0.022 to 0.496) and 0.037 (95% CI, 0.022 to 0.061) in small cell and non-small cell carcinomas, respectively ([Table 2](#t2-jptm-2020-06-08){ref-type="table"}, [Fig. 2](#f2-jptm-2020-06-08){ref-type="fig"}). There was a significant difference in PAX8 expression between small cell and non-small cell carcinomas by the meta-regression test (p=.049). Detailed subgroup analysis was performed based on tumor subtypes of non-small cell carcinomas. PAX8 expression rates were 0.013 (95% CI, 0.006 to 0.031), 0.040 (95% CI, 0.016 to 0.097), and 0.113 (95% CI, 0.059 to 0.205) in adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, respectively. The PAX8 expression rate was 0.071 (95% CI, 0.004 to 0.577) in micropapillary carcinoma and 0.050 (95% CI, 0.007 to 0.272) in large cell neuroendocrine carcinoma. Moreover, the PAX8 expression rate of metastatic cancers from the lung to other organs was investigated; the estimated PAX8 expression rates were similar to those of primary lung cancers. The PAX8 expression rates in metastatic lung adenocarcinoma and squamous cell carcinoma were 0.050 (95% CI, 0.003 to 0.475) and 0.071 (95% CI, 0.004 to 0.577), respectively ([Table 3](#t3-jptm-2020-06-08){ref-type="table"}). In addition, the PAX8 expression rate of metastatic small cell carcinomas from the lungs was 0.067 (95% CI, 0.009 to 0.352).

PAX8 expression in metastatic carcinomas from various organs
------------------------------------------------------------

The PAX8 expression rates of metastatic carcinomas to the lung were investigated to elucidate the differential role of PAX8 immunohistochemistry. Metastatic carcinomas to the lung showed different PAX8 expression rates, ranging from 1.8% to 94.9% ([Table 4](#t4-jptm-2020-06-08){ref-type="table"}, [Fig. 3](#f3-jptm-2020-06-08){ref-type="fig"}). Among metastatic carcinomas to the lung, PAX8 expression rates in metastatic carcinomas from the female genital organs, kidney, and thyroid were 0.746 (95% CI, 0.501 to 0.895), 0.876 (95% CI, 0.796 to 0.928), and 0.879 (95% CI, 0.697 to 0.959), respectively. There were significant differences in PAX8 expression rates between primary lung cancers and metastatic carcinomas from the female genital organs, kidneys, and thyroid gland.

DISCUSSION
==========

Because PAX8 expression can differ by tumor origin, PAX8 may be useful in differentiating malignant tumors of various origins. Some studies reported that PAX8 expression was absent or very low in primary lung cancers \[[@b4-jptm-2020-06-08],[@b8-jptm-2020-06-08]-[@b24-jptm-2020-06-08]\], whereas others reported high PAX8 expressions of up to 66.7% \[[@b8-jptm-2020-06-08],[@b14-jptm-2020-06-08],[@b16-jptm-2020-06-08],[@b21-jptm-2020-06-08]-[@b24-jptm-2020-06-08]\]; thus detailed information on PAX8 expression according to tumor subtypes of lung cancer was unclear. In this meta-analysis, we evaluated the diagnostic roles of PAX8 immunohistochemical expression in primary lung cancers and metastatic carcinomas to the lung.

It is difficult to obtain conclusive data from individual studies because of the small sample size and difference in evaluation methods. PAX8 expression was found in 0%--66.7%, 0%--12.5%, and 0%--33.3% cases of small cell lung carcinoma, adenocarcinoma, and squamous cell carcinoma of the lung, respectively \[[@b4-jptm-2020-06-08],[@b8-jptm-2020-06-08]-[@b24-jptm-2020-06-08]\]. Unlike previous studies, estimated PAX8 expression rates were 12.9% and 3.6% in small cell and non-small cell carcinomas, respectively. However, the cause for discrepancy in the results between the present meta-analysis and previous studies could not be determined. Based on our results, the PAX8 expression was significantly higher in small cell carcinoma than in nonsmall cell carcinoma (p=.049 in the meta-regression test). Clinically, the usefulness of differentiation between small cell and non-small cell carcinomas is limited, regardless of statistical significance. This may be due to the low expression rates of PAX8 in both small cell and non-small cell lung carcinomas. In addition, a significant difference in PAX8 expression between tumor subtypes of primary lung cancers was not identified in the metaregression tests. Therefore, the usefulness of PAX8 expression in the differentiation of tumor subtypes of primary lung cancer is limited.

In daily practice, pathologists have to diagnose various metastatic cancers to the lung, which is a common metastatic site for extrapulmonary carcinomas \[[@b3-jptm-2020-06-08]\]. The histologic diagnosis of some metastatic cancers of unknown origin is challenging, especially when the metastatic cancer to the lung has histologic findings similar to a primary lung cancer. In previous studies, tumors that originated from the female genital organs, kidney, and thyroid gland were found to have high PAX8 expressions. PAX8 expression rates of metastatic carcinoma from these organs were 62.9%-- 94.9%. However, metastatic carcinomas from other organs showed lower PAX8 expression than the metastatic carcinoma from the female genital organs, kidney, and thyroid gland (1.8%--16.7% vs. 62.9%--94.9%). Taken together, these results indicate that metastatic carcinomas from the female genital organs, kidney, and thyroid gland can be differentiated from primary lung cancers based on different PAX8 expression rates.

Because lung cancer can metastasize to other organs, PAX8 expression levels were investigated in metastatic lung cancers \[[@b33-jptm-2020-06-08]\]. In this study, there was no significant difference in PAX8 expression between primary lung cancers and metastatic cancers to the lung. For example, lung adenocarcinoma metastasizes to the ovary at an extremely low rate \[[@b33-jptm-2020-06-08]\]. The metastatic lung cancers can be easily differentiated from the primary ovarian cancers using immunohistochemistry for TTF-1, Napsin A, and PAX8 \[[@b7-jptm-2020-06-08]\].

The most common site of distant metastasis for thyroid carcinomas is the lung \[[@b34-jptm-2020-06-08]\]. In addition, some lung cancers, up to 3.1%, can metastasize to the thyroid glands \[[@b35-jptm-2020-06-08],[@b36-jptm-2020-06-08]\]. Thus, the need for differentiating between lung and thyroid carcinomas may be common in daily practice. The histologic findings of papillary thyroid carcinoma can overlap with some non-mucinous bronchioloalveolar and papillary types of lung adenocarcinoma \[[@b17-jptm-2020-06-08]\]. Because TTF-1 is expressed in both thyroid and lung cancers, other specific markers are needed for differentiation in daily practice. In our results, PAX8 was highly expressed in metastatic thyroid cancer of the lung, similar to primary thyroid cancers \[[@b23-jptm-2020-06-08]\]. According to these findings, cases with TTF-1 and PAX8 expressions theoretically can be considered as metastatic thyroid cancer. On the other hand, cases with only TTF-1 expression can be considered as primary lung cancer. The PAX8 expression rates of anaplastic thyroid carcinomas were reported to be 50.0%--100.0% \[[@b22-jptm-2020-06-08],[@b37-jptm-2020-06-08]\]. In addition, the histologic findings, such as anaplastic spindle and giant cells, can overlap between pleomorphic carcinoma of the lung and anaplastic thyroid carcinoma \[[@b1-jptm-2020-06-08],[@b38-jptm-2020-06-08]\]. The TTF-1 expression rates were higher in lung pleomorphic carcinoma than in anaplastic thyroid carcinoma \[[@b39-jptm-2020-06-08],[@b40-jptm-2020-06-08]\]. Because TTF-1 expression can be lower in anaplastic thyroid carcinoma than in other types of thyroid carcinoma, the histologic findings of the original tumor are important for differentiation. Therefore, the immunohistochemical markers, including PAX8, can be useful for the differential diagnosis of malignant tumors of the lung.

PAX8 expression was evaluated by monoclonal or polyclonal antibodies. However, the difference in clonality of the primary PAX8 antibody is not clear in primary lung cancers. This point may be necessary for defining PAX8 expression because PAX8 expression in primary lung cancers was low or absent. In previous studies, the immunohistochemistry using PAX8 polyclonal antibody showed cross-reactivity with other PAX families and detected immunoreactivity in normal tissues and tumors represented by B lymphocytes \[[@b41-jptm-2020-06-08]-[@b43-jptm-2020-06-08]\]. Some studies reported different PAX8 expression rates according to the clonality of antibodies in the same tissues \[[@b22-jptm-2020-06-08],[@b23-jptm-2020-06-08]\]. Toriyama et al. (2014) \[[@b22-jptm-2020-06-08]\] reported that PAX8 expression was only detected in immunohistochemistry with polyclonal antibody but not with a monoclonal antibody. However, Vidarsdottir et al. (2019) \[[@b23-jptm-2020-06-08]\] detected PAX8 expression in primary lung cancers using a monoclonal antibody. In our results, PAX8 expression rates of small cell carcinoma were 0.113 (95% CI, 0.001 to 0.968) and 0.141 (95% CI, 0.019 to 0.585) in monoclonal and polyclonal antibodies, respectively (data not shown). In addition, in non-small cell lung carcinoma, PAX8 expression rates were 0.020 (95% CI, 0.009 to 0.044) and 0.057 (95% CI, 0.033 to 0.095) in monoclonal and polyclonal antibodies, respectively (data not shown). However, the difference in PAX8 expression between clonalities of PAX8 antibody was significant in non-small cell lung carcinoma but not in small cell lung carcinoma (p=.030 and p= .993 in the meta-regression test, respectively). Therefore, the difference in PAX8 expression rates as detected by monoclonal and polyclonal antibodies is uncertain. However, regardless of these differences, both monoclonal and polyclonal antibodies can be useful for differentiating between metastatic carcinomas with high expression rates of PAX8 and primary lung cancers with low expression rates of PAX8. From previous studies, the high expression rate of PAX8 immunohistochemistry using a polyclonal antibody can be considered a highly sensitive method. Conversely, the low expression rate of PAX8 immunohistochemistry using a monoclonal antibody can be considered a highly specific method. As described above, the possibility of misinterpretation for other components, including normally placed components, should be considered. In addition, immunohistochemical staining techniques can affect the positive rates of PAX8, regardless of the clonality of antibody.

This study has some limitations. First, subgroup analysis based on clonality of antibody could not be performed for metastatic carcinomas from other organs due to insufficient information. Second, the detailed information for PAX8 expression of metastatic lung cancer based on metastatic organs could not be obtained due to insufficient information. Third, although the pleura is the most common metastatic site of lung cancer, a comparison of PAX8 expressions between the primary and metastatic tumors of the pleura could not be performed due to a lack of information. Fourth, subgroup analysis based on differentiation of tumors and subtypes of adenocarcinoma could not be performed due to insufficient information on eligible studies. Fifth, detailed analyses for some uncommon subtypes of the primary lung cancer with low incidence were not performed due to the small sample size of patients with these cancers. Lastly, the impact of changed diagnostic criteria of primary lung cancers could not be investigated because we did not include cases applying revised diagnostic criteria in eligible studies.

In conclusion, our results showed that PAX8 expression was lower in primary lung cancer than in metastatic carcinoma of the lung. However, the diagnostic role of PAX8 expression in differentiating tumor subtypes of primary lung cancers is limited due to low rates of PAX8 immunohistochemistry. In daily practice, PAX8 immunohistochemistry can be useful for the diagnosis of metastatic cancer from the female genital organs, kidney, and thyroid gland.
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###### 

Main characteristics of the eligible studies

  Study                                                   Location   Antibody manufacturer clonality   Clonality organ   Tumor subtype              PAX8 IHC   
  ------------------------------------------------------- ---------- --------------------------------- ----------------- -------------------------- ---------- -----
  Asirvatham et al. (2014) \[[@b8-jptm-2020-06-08]\]      USA        Polyclonal                        Lung              ND                         1          14
  Bi et al. (2019) \[[@b9-jptm-2020-06-08]\]              China      Monoclonal                        Metastatic                                   0          7
  Bi et al. (2016) \[[@b10-jptm-2020-06-08]\]             China      Polyclonal                        Lung              NEC                        0          20
  El-Maqsoud et al. (2016) \[[@b11-jptm-2020-06-08]\]     Egypt      Monoclonal                        Lung              Adenocarcinoma             0          30
                                                                     Monoclonal                        Lung              Squamous cell carcinom     0          15
                                                                     Monoclonal                        Lung              Large cell carcinoma       0          5
                                                                     Monoclonal                        Metastatic                                   88         55
  Gailey et al. (2013) \[[@b12-jptm-2020-06-08]\]         USA        Polyclonal                        Lung              Squamous cell carcinoma    0          12
  Heidarpour et al. (2014) \[[@b13-jptm-2020-06-08]\]     Iran       Polyclonal                        Lung              ND                         0          5
  Laury et al. (2011) \[[@b14-jptm-2020-06-08]\]          USA        Polyclonal                        Lung              Adenocarcinoma             0          120
                                                                     Polyclonal                        Lung              squamous cell carcinoma    4          8
                                                                     Polyclonal                        Lung              Adenosquamous carcinoma    0          3
                                                                     Polyclonal                        Lung              Small cell carcinoma       0          9
  Lotan et al. (2009) \[[@b15-jptm-2020-06-08]\]          USA        Polyclonal                        Lung              Micropapillary carcinoma   0          6
  Mentrikoski et al. (2014) \[[@b16-jptm-2020-06-08]\]    USA        Polyclonal                        Lung              Adenocarcinoma             1          7
                                                                     Polyclonal                        Lung              Squamous cell carcinoma    0          3
  Nonaka et al. (2008) \[[@b17-jptm-2020-06-08]\]         USA        Polyclonal                        Lung              Adenocarcinoma             0          114
                                                                     Polyclonal                        Lung              Squamous cell carcinoma    0          29
                                                                     Polyclonal                        Lung              Large cell carcinoma       0          4
  Ozcan et al. (2011) \[[@b18-jptm-2020-06-08]\]          USA        Polyclonal                        Lung              Squamous cell carcinoma    0          4
                                                                     Polyclonal                        Lung              Adenocarcinoma             0          7
                                                                     Polyclonal                        Lung              Small cell carcinoma       0          12
                                                                     Polyclonal                        From lung         Small cell carcinoma       1          14
                                                                     Polyclonal                        From lung         Adenocarcinoma             0          9
                                                                     Polyclonal                        From lung         Squamous cell carcinoma    0          6
  Suzuki et al. (2015) \[[@b19-jptm-2020-06-08]\]         Japan      Polyclonal                        Lung              Squamous cell carcinoma    0          5
  Tacha et al. (2013) \[[@b20-jptm-2020-06-08]\]          USA        Monoclonal                        Lung              ND                         0          50
  Tacha et al. (2011) \[[@b21-jptm-2020-06-08]\]          USA        Polyclonal                        Lung              Squamous cell carcinoma    1          48
                                                                     Polyclonal                        Lung              Adenosquamous carcinoma    0          11
                                                                     Polyclonal                        Lung              Adenocarcinoma             0          15
  Toriyama et al. (2014) \[[@b22-jptm-2020-06-08]\]       Japan      Polyclonal                        Lung              Adenocarcinoma             6          247
                                                                     Polyclonal                        Lung              Squamous cell carcinoma    3          155
                                                                     Polyclonal                        Lung              LCNEC                      17         89
                                                                     Polyclonal                        Lung              Small cell carcinoma       27         40
                                                                     Polyclonal                        Lung              Pleomorphic carcinoma      0          41
                                                                     Polyclonal                        Lung              Large cell carcinoma       2          9
                                                                     Monoclonal                        Lung              Adenocarcinoma             0          253
                                                                     Monoclonal                        Lung              Squamous cell carcinoma    0          158
                                                                     Monoclonal                        Lung              LCNEC                      0          106
                                                                     Monoclonal                        Lung              Small cell carcinoma       0          67
                                                                     Monoclonal                        Lung              Pleomorphic carcinoma      0          41
                                                                     Monoclonal                        Lung              Large cell carcinoma       0          11
  Vidarsdottir et al. (2019) \[[@b23-jptm-2020-06-08]\]   Sweden     Monoclonal                        Lung              Adenocarcinoma             2          429
                                                                     Monoclonal                        Lung              Squamous cell carcinom     4          198
                                                                     Monoclonal                        Lung              Large cell carcinoma       2          7
                                                                     Monoclonal                        Lung              Sarcomatoid carcinoma      0          6
                                                                     Monoclonal                        Lung              Small cell carcinoma       2          1
                                                                     Monoclonal                        Lung              Large cell NEC             1          19
                                                                     Monoclonal                        Metastatic                                   55         251
  Weissferdt et al. (2013) \[[@b24-jptm-2020-06-08]\]     USA        Polyclonal                        Lung              NEC                        2          23
  Ye et al. (2012) \[[@b4-jptm-2020-06-08]\]              USA        ND                                Lung              Adenocarcinoma             0          120
                                                                     ND                                Metastatic                                   45         56

ND, no description; NEC, neuroendocrine carcinoma; LCNEC, large cell neuroendocrine carcinoma.

###### 

The estimated rates of PAX8 immunohistochemical expressions in primary lung cancers

                              No. of subsets   Fixed effect (95% CI)   Heterogeneity test p-value   Random effect (95% CI)   Egger's test p-value
  --------------------------- ---------------- ----------------------- ---------------------------- ------------------------ ----------------------
  Lung, primary               45               0.092 (0.075--0.114)    \< .001                      0.042 (0.025--0.071)     \< .001
   Small cell carcinoma       5                0.350 (0.254--0.461)    .002                         0.129 (0.022--0.496)     .185
   Non-small cell carcinoma   3,537            0.054 (0.042--0.071)    \< .001                      0.036 (0.021--0.061)     .022
                                               0.055 (0.042--0.071)                                 0.037 (0.022--0.061)     .018
   Adenocarcinoma             10               0.016 (0.009--0.027)    .113                         0.013 (0.006--0.031)     .493
   Micropapillary carcinoma   1                0.071 (0.004--0.577)    \> .99                       0.071 (0.004--0.577)     \-
   Squamous cell carcinoma    11               0.041 (0.025--0.067)    .004                         0.040 (0.016--0.097)     .907
   Large cell carcinoma       8                0.139 (0.094--0.199)    .216                         0.113 (0.059--0.205)     .101
   Large cell NEC             3                0.136 (0.087--0.205)    .020                         0.050 (0.007--0.272)     .192
   Sarcomatoid carcinoma      1                0.071 (0.004--0.577)    \> .99                       0.071 (0.004--0.577)     \-
   Pleomorphic carcinoma      2                0.012 (0.002--0.080)    \> .99                       0.012 (0.002--0.080)     \-
   Adenosquamous carcinoma    2                0.071 (0.010--0.373)    .569                         0.071 (0.010--0.373)     \-

CI, confidence interval; NEC, neuroendocrine carcinoma.

###### 

The estimated rates of PAX8 immunohistochemical expressions in metastatic lung cancer

                             No. of subsets   Fixed effect (95% CI)   Heterogeneity test p-value   Random effect (95% CI)   Egger's test p-value
  -------------------------- ---------------- ----------------------- ---------------------------- ------------------------ ----------------------
  Lung, metastatic           3                0.063 (0.016--0.220)    .980                         0.063 (0.016--0.220)     .755
   Adenocarcinoma            1                0.050 (0.003--0.475)    \> .99                       0.050 (0.003--0.475)     \-
   Squamous cell carcinoma   1                0.071 (0.004--0.577)    \> .99                       0.071 (0.004--0.577)     \-
   Small cell carcinoma      1                0.067 (0.009--0.352)    \> .99                       0.067 (0.009--0.352)     \-

CI, confidence interval.

###### 

The estimated rates of PAX8 immunohistochemical expressions in metastatic carcinoma to the lung

                                                                           No. of subsets   Fixed effect (95% CI)   Heterogeneity test p-value   Random effect (95% CI)   Egger's test p-value
  ------------------------------------------------------------------------ ---------------- ----------------------- ---------------------------- ------------------------ ----------------------
  Metastatic carcinoma                                                     39               0.492 (0.412--0.573)    \< .001                      0.337 (0.191--0.523)     .005
   Adrenal cortex                                                          1                0.167 (0.010--0.806)    \> .99                       0.167 (0.010--0.806)     \-
   Appendix                                                                1                0.100 (0.006--0.674)    \> .99                       0.100 (0.006--0.674)     \-
   Breast                                                                  3                0.039 (0.010--0.142)    .991                         0.039 (0.010--0.142)     .701
   Colorectum                                                              3                0.018 (0.006--0.056)    .468                         0.018 (0.006--0.056)     .049
   Esophagus                                                               1                0.125 (0.007--0.734)    \> .99                       0.125 (0.007--0.734)     \-
   Female genital organ^[a](#tfn1-jptm-2020-06-08){ref-type="table-fn"}^   7                0.717 (0.571--0.828)    .042                         0.746 (0.501--0.895)     .570
    Ovary                                                                  4                0.641 (0.423--0.813)    .038                         0.629 (0.243--0.899)     .908
     Mucinous carcinoma                                                    1                0.600 (0.297--0.842)    \> .99                       0.600 (0.297--0.842)     \-
     Serous carcinoma                                                      1                0.955 (0.552--0.997)    \> .99                       0.955 (0.552--0.997)     \-
    Uterine endometrium                                                    2                0.949 (0.713--0.993)    .615                         0.949 (0.713--0.993)     \-
   Kidney-RCC                                                              5                0.876 (0.796--0.928)    .884                         0.876 (0.796--0.928)     .213
    Clear cell RCC                                                         1                0.923 (0.609--0.989)    \> .99                       0.923 (0.609--0.989)     \-
    Chromophobe RCC                                                        1                0.833 (0.369--0.977)    \> .99                       0.833 (0.369--0.977)     \-
    Papillary RCC                                                          1                0.958 (0.575--0.997)    \> .99                       0.958 (0.575--0.997)     \-
   Liver                                                                   3                0.063 (0.013--0.260)    .914                         0.063 (0.013--0.260)     .048
   Pancreatobiliary                                                        2                0.133 (0.026--0.466)    .472                         0.133 (0.026--0.466)     \-
   Prostate                                                                2                0.072 (0.014--0.290)    .678                         0.072 (0.014--0.290)     \-
   Salivary gland                                                          2                0.071 (0.010--0.370)    \> .99                       0.071 (0.010--0.370)     \-
   Small bowel                                                             1                0.167 (0.010--0.806)    \> .99                       0.167 (0.010--0.806)     \-
   Stomach                                                                 1                0.083 (0.005--0.622)    \> .99                       0.083 (0.005--0.622)     \-
   Testis                                                                  1                0.125 (0.007--0.734)    \> .99                       0.125 (0.007--0.734)     \-
   Thyroid                                                                 4                0.879 (0.697--0.959)    .421                         0.879 (0.697--0.959)     .839
    Papillary carcinoma                                                    1                0.938 (0.665--0.991)    \> .99                       0.938 (0.665--0.991)     \-
    Follicular carcinoma                                                   1                0.967 (0.634--0.998)    \> .99                       0.967 (0.634--0.998)     \-
   Urinary system                                                          2                0.171 (0.032--0.564)    .261                         0.165 (0.024--0.613)     \-

CI, confidence interval; RCC, renal cell carcinoma.

Included uterine corpus and cervix and ovary.
